Journal ArticleDOI
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Sunder Mudaliar,Robert R. Henry,Arun J. Sanyal,Linda Morrow,Hanns-Ulrich Marschall,Mark Kipnes,Luciano Adorini,Cathi Sciacca,Paul Clopton,E. Castelloe,Paul Dillon,Mark Pruzanski,David Shapiro +12 more
Reads0
Chats0
TLDR
Administration of 25 or 50 mg OCA for 6 weeks was well tolerated, increased insulin sensitivity, and reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.About:
This article is published in Gastroenterology.The article was published on 2013-09-01. It has received 794 citations till now. The article focuses on the topics: Insulin resistance & Nonalcoholic fatty liver disease.read more
Citations
More filters
Journal ArticleDOI
Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
Kumiko Shiba,Kyoichiro Tsuchiya,Chikara Komiya,Yasutaka Miyachi,Kentaro Mori,Noriko Shimazu,Shinobu Yamaguchi,Naomi Ogasawara,Makoto Katoh,Michiko Itoh,Takayoshi Suganami,Yoshihiro Ogawa +11 more
TL;DR: Evidence is provided that SGLT2 inhibitors represent the unique class of drugs that can attenuate or delay the onset of NASH and eventually hepatocellular carcinoma, at least partly, through “healthy adipose expansion”.
Journal ArticleDOI
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
TL;DR: A review on the role of the Farnesoid X receptor (FXR) in metabolic diseases and liver cancer is presented in this article, where the potential for development of targeted drugs are summarized.
Journal ArticleDOI
Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy
TL;DR: Evidence indicates that bile acid diarrhoea accounts for a sizeable proportion of patients who would otherwise be diagnosed with IBS, and the role of the ileal hormone FGF19 in BAD has been strengthened: a prospective clinical study has confirmed low F GF19 levels in BAD, and so a test to measure these levels could be developed for diagnosis.
Journal ArticleDOI
Bile acid receptors in non-alcoholic fatty liver disease.
TL;DR: Recent advances on the role of both FXR and TGR5 in regulating hepatic triglyceride metabolism and inflammatory responses under normal and disease conditions are focused on.
Journal ArticleDOI
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Kenneth Cusi,Kenneth Cusi +1 more
TL;DR: Increased clinical awareness and improved screening strategies are needed, to translate recent treatment progress into early treatment and improved quality of life for patients with type 2 diabetes and NASH.
References
More filters
Journal ArticleDOI
Diagnosis and Classification of Diabetes Mellitus
TL;DR: The chronic hyperglycemia of diabetes is associated with long-term damage, dys-function, and failure of differentorgans, especially the eyes, kidneys, nerves, heart, and blood vessels.
Journal ArticleDOI
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
TL;DR: Methods for the quantification of beta-cell sensitivity to glucose (hyperglycemic clamp technique) and of tissue sensitivity to insulin (euglycemic insulin clamp technique] are described.
Journal ArticleDOI
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Takeshi Inagaki,Mihwa Choi,Antonio Moschetta,Li Peng,Carolyn L. Cummins,Jeffrey G. McDonald,Guizhen Luo,Stacey A. Jones,Bryan Goodwin,James A. Richardson,Robert D. Gerard,Joyce J. Repa,David J. Mangelsdorf,Steven A. Kliewer +13 more
TL;DR: It is demonstrated that fibroblast growth factor 15 signals from intestine to liver to repress the gene encoding cholesterol 7alpha-hydroxylase (CYP7A1), which catalyzes the first and rate-limiting step in the classical bile acid synthetic pathway.
Journal ArticleDOI
Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.
Sama I. Sayin,Annika Wahlström,Jenny Felin,Sirkku Jäntti,Hanns-Ulrich Marschall,Krister Bamberg,Bo Angelin,Tuulia Hyötyläinen,Matej Orešič,Fredrik Bäckhed,Fredrik Bäckhed +10 more
TL;DR: It is suggested that the gut microbiota not only regulates secondary bile acids metabolism but also inhibits bile acid synthesis in the liver by alleviating FXR inhibition in the ileum.
Journal ArticleDOI
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
TL;DR: Results suggest that modulation of FXR activity and BA metabolism may open new attractive pharmacological approaches for the treatment of the metabolic syndrome and type 2 diabetes.
Related Papers (5)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more